KYOWA HAK KIRIN - Dusseldorf Stock Exchang (KY4 DU) stock market data APIs
€14.2317
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
KYOWA HAK KIRIN - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for KY4.DU.
Prev. Close
14.2317
Open
14.2317
High
14.2317
Low
14.2317
52 wk Range
12.2487-19.5145
Market Cap
13 438 M
EPS
34.44
Dividends (Yield)
2.0792
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang data using free add-ons & libraries
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang Fundamental Data
KYOWA HAK KIRIN - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2024-10-31
- EPS/Forecast: 35.74
Get KYOWA HAK KIRIN - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
KYOWA HAK KIRIN - Dusseldorf Stock Exchang News
New
Amgen Inc (AMGN) Releases Top-Line Results From ASCEND Study of Rocatinlimab
Amgen Inc. (NASDAQ:AMGN) is one of the Blue Chip Stocks to Buy with the Lowest PE Ratios. On September 8, Amgen Inc. (NASDAQ:AMGN), along with Kyowa Kirin preliminary top-line results from the ASCEND ...
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress
Princeton, NJ and TOKYO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational T-cel...
Amgen (AMGN) And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study
Amgen and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new therapy for atopic dermatitis, which could potentially pique investor interest. Despi...
The Bull Case For Amgen (AMGN) Could Change Following Phase 3 Rocatinlimab Data Release
Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy rocatinlimab in approximately 2,600 adults and adolescents with moderate to s...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
